Juan Felix Espinosa
Juan Felix Espinosa has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Teodor Parella
Universitat Autònoma de Barcelona Campus UAB
2 shared publications - Albert Eric Schultze
Lilly Research Laboratories, Indianapolis, Indiana, USA
1 shared publication Amanda K. Nosie
Lilly Research Laboratories, Indianapolis, USA
1 shared publicationAna Maria Escribano
Lilly Research Laboratories, Alcobendas, Spain
1 shared publicationAnthony Borel
Lilly Research Laboratories, Indianapolis, USA
1 shared publicationBirgit T. Priest
Lilly Research Laboratories, Indianapolis, USA
1 shared publication
Latest Publications
- Open Access
- 8 May 2024
- Published by Springer Nature in Nature
- Vol. 629 (8013) , 945-950
Discovery of potent small-molecule inhibitors of lipoprotein(a) formation
Lipoprotein(a) (Lp(a)), an independent, causal cardiovascular risk factor, is a lipoprotein particle that is formed by the interaction of a low-density lipoprotein (LDL) particle and apolipoprotein(a) (apo(a))1,2. Apo(a) first binds to lysine residues of apolipoprotein B-100 (apoB-100) on LDL through the Kringle IV (KIV) 7 and 8 domains, before a disulfide bond forms between apo(a) and apoB-100 to create Lp(a) (refs. 3–7). Here we show that the first step of Lp(a) formation can be inhibited through small-molecule interactions with apo(a) KIV7–8. We identify compounds that bind to apo(a) KIV7–8, and, through chemical optimization and further application of multivalency, we create compounds with subnanomolar potency that inhibit the formation of Lp(a). Oral doses of prototype compounds and a potent, multivalent disruptor, LY3473329 (muvalaplin), reduced the levels of Lp(a) in transgenic mice and in cynomolgus monkeys. Although multivalent molecules bind to the Kringle domains of rat plasminogen and reduce plasmin activity, species-selective differences in plasminogen sequences suggest that inhibitor molecules will reduce the levels of Lp(a), but not those of plasminogen, in humans. These data support the clinical development of LY3473329—which is already in phase 2 studies—as a potent and specific orally administered agent for reducing the levels of Lp(a).
- 8 May 2024
- Published by Springer Nature in Nature
- Vol. 629 (8013) , 945-950
Open AccessDiscovery of potent small-molecule inhibitors of lipoprotein(a) formation
Lipoprotein(a) (Lp(a)), an independent, causal cardiovascular risk factor, is a lipoprotein particle that is formed by the interaction of a low-density lipoprotein (LDL) particle and apolipoprotein(a) (apo(a))1,2. Apo(a) first binds to lysine residues of apolipoprotein B-100 (apoB-100) on LDL through the Kringle IV (KIV) 7 and 8 domains, before a disulfide bond forms between apo(a) and apoB-100 to create Lp(a) (refs. 3–7). Here we show that the first step of Lp(a) formation can be inhibited through small-molecule interactions with apo(a) KIV7–8. We identify compounds that bind to apo(a) KIV7–8, and, through chemical optimization and further application of multivalency, we create compounds with subnanomolar potency that inhibit the formation of Lp(a). Oral doses of prototype compounds and a potent, multivalent disruptor, LY3473329 (muvalaplin), reduced the levels of Lp(a) in transgenic mice and in cynomolgus monkeys. Although multivalent molecules bind to the Kringle domains of rat plasminogen and reduce plasmin activity, species-selective differences in plasminogen sequences suggest that inhibitor molecules will reduce the levels of Lp(a), but not those of plasminogen, in humans. These data support the clinical development of LY3473329—which is already in phase 2 studies—as a potent and specific orally administered agent for reducing the levels of Lp(a).
- 21 February 2008
- Published by Elsevier in Tetrahedron Letters
- Vol. 49 (16) , 2562-2565
First experimental determination of two-bond 13C isotopic effects on 1H NMR chemical shifts
- 21 February 2008
- Published by Elsevier in Tetrahedron Letters
- Vol. 49 (16) , 2562-2565
First experimental determination of two-bond 13C isotopic effects on 1H NMR chemical shifts
- 9 March 2007
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 72 (9) , 3166-3170
A Simple Method for Measuring Long-Range 1H−13C Coupling Constants in Organic Molecules
This study presents a simple method for measuring long-range heteronuclear coupling constants between protons and proton-bearing carbons. The approach involves recording two conventional 1D-TOCSY experiments in which the offset of the selective proton pulse is set on the low- and high-frequency 13C satellites of an isolated proton signal, Hi. Long-range heteronuclear coupling values between the 13Ci bonded to Hi and the protons Hj,k...n that belong to the same spin system were easily determined from the relative displacement of the relayed Hj,k...n signals in the satellite-selective TOCSY spectra. The sense of the displacement indicated the sign of the coupling constants.
- 9 March 2007
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 72 (9) , 3166-3170
A Simple Method for Measuring Long-Range 1H−13C Coupling Constants in Organic Molecules
This study presents a simple method for measuring long-range heteronuclear coupling constants between protons and proton-bearing carbons. The approach involves recording two conventional 1D-TOCSY experiments in which the offset of the selective proton pulse is set on the low- and high-frequency 13C satellites of an isolated proton signal, Hi. Long-range heteronuclear coupling values between the 13Ci bonded to Hi and the protons Hj,k...n that belong to the same spin system were easily determined from the relative displacement of the relayed Hj,k...n signals in the satellite-selective TOCSY spectra. The sense of the displacement indicated the sign of the coupling constants.